ArticleWorld journal of hepatology2019
Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study.
Article in World journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Synchronous Hepatocellular and Intrahepatic Cholangiocellular Carcinoma With Predominant Ductal Plate Malformation Pattern. A Case Report and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Review
- New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?Journal of personalized medicine · 2024Review
- Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- Activation of CTU2 expression by LXR promotes the development of hepatocellular carcinoma.Cell biology and toxicology · 2024Article
- Design, Synthesis and Biological Assessment ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms.International journal of molecular sciences · 2023Article
- The expression of VEGF and cyclin D1/EGFR in common primary liver carcinomas in Egypt: an immunohistochemical study.Ecancermedicalscience · 2023Article
- Cytokines and Hepatocellular Carcinoma: Biomarkers of a Deadly Embrace.Journal of personalized medicine · 2022Review
- Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma.Frontiers in oncology · 2022Review
- Antiangiogenic and Proapoptotic Activities of Atorvastatin and Ganoderma lucidum in Tumor Mouse Model via VEGF and Caspase-3 Pathways.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Benefits of the 8th American Joint Committee on Cancer System for Hepatocellular Carcinoma Staging.Journal of gastrointestinal cancer · 2021Article
- Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation.Metallomics : integrated biometal science · 2020Article
- Epithelial Mesenchymal and Endothelial Mesenchymal Transitions in Hepatocellular Carcinoma: A Review.BioMed research international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough hepatocellular carcinoma (HCC) is one of the most vascular solid tumors, antiangiogenic therapy has not induced the expected results.
aimTo uncover immunohistochemical (IHC) aspects of angiogenesis in HCC.
methodsA retrospective cohort study was performed and 50 cases of HCC were randomly selected. The angiogenesis particularities were evaluated based on the IHC markers Cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) A and the endothelial area (EA) was counted using the antibodies CD31 and CD105.
resultsThe angiogenic phenotype evaluated with VEGF-A was more expressed in small tumors without vascular invasion (pT1), whereas COX-2 was rather expressed in dedifferentiated tumors developed in non-cirrhotic liver. The CD31-related EA value decreased in parallel with increasing COX-2 intensity but was higher in HCC cases developed in patients with cirrhosis. The CD105-related EA was higher in tumors developed in patients without associated hepatitis.
conclusionIn patients with HCC developed in cirrhosis, the newly formed vessels are rather immature and their genesis is mediated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.